ZOLEDRONIC ACID ROLE IN SRES PREVENTION: AN ADVANTAGE FOR ALL PATIENTS WITH ADVANCED NSCLC AND BONE METASTASES?

被引：0
|
作者：
Del Signore, E. [1 ]
De Marinis, F. [2 ]
机构：
[1] San Camillo Forlanini High Specializat Hosp, Rome, Italy
[2] AO San Camillo Forlanini, Dept Lung Dis, Rome, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [21] Zoledronic acid is being investigated for the prevention of bone metastases in patients with early-stage breast cancer
    Coleman, R
    Gralow, J
    Bell, R
    Lipton, A
    BONE, 2004, 34 : S85 - S85
  • [22] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases.
    Lipton, A.
    Chen, Y. M.
    Milton, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S62 - S62
  • [23] Treatment of Bone Metastases in Lung Cancer: The Actual Role of Zoledronic Acid
    Ricciardi, Serena
    de Marinis, Filippo
    REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (03) : 205 - 211
  • [24] Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
    Armeni, E.
    Hayes, A. R.
    Gopaul, A.
    Aristidou, I
    Navalkissoor, S.
    Mandair, D.
    Khoo, B.
    Caplin, M.
    Grossman, A.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2020, 110 : 220 - 220
  • [25] Zoledronic acid treatment in advanced non- small cell lung cancer patients with bone metastases
    Song, Zhengbo
    Zhang, Yiping
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [26] Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases
    Zhengbo Song
    Yiping Zhang
    Medical Oncology, 2014, 31
  • [27] PII trial of zoledronic acid in NSCLC pts with bone metastases and elevated marker of osteoclast activity
    Fukuda, Minoru
    Kitazaki, Takeshi
    Harada, Taishi
    Suetsugu, Takayuki
    Kawasaki, Masayuki
    Wataya, Hiroshi
    Furugen, Makoto
    Tokunaga, Shoji
    Takayama, Koichi
    Sugio, Kenji
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Hypogonadism causes bone loss and increased bone metastases in a model of mixed osteolytic/osteoblastic metastases: Prevention by zoledronic acid
    Padalecki, SS
    Carreon, M
    Grubbs, B
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (09) : 1589 - 1590
  • [29] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Tas, Faruk
    Duranyildiz, Derya
    Oguz, Hilal
    Camlica, Hakan
    Yasasever, Vildan
    Topuz, Erkan
    MEDICAL ONCOLOGY, 2008, 25 (03) : 346 - 349
  • [30] Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases
    Leto, G
    Badalamenti, G
    Arcara, C
    Crescimanno, M
    Flandina, C
    Tumminello, FM
    Incorvaia, L
    Gebbia, N
    Fulfaro, F
    ANTICANCER RESEARCH, 2006, 26 (1A) : 23 - 26
12345